To identify the specific type of T cells that responded to PD-1/PD-L1 blockage, a scRNA-seq data of BM cells from relapsed or refractory AML patients who were pre- and post-treated with azacytidine and nivolumab was analyzed. The gene discussed is PDCD1; the disease is acute myeloid leukemia.